MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Zai Lab Ltd ADR

Затворен

СекторЗдравеопазване

33.64 2.69

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

32.72

Максимум

33.94

Ключови измерители

By Trading Economics

Приходи

7.7M

-41M

Продажби

3.5M

110M

Марж на печалбата

-37.032

Служители

1,869

EBITDA

1.4M

-55M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+59.84% upside

Дивиденти

By Dow Jones

Следващи печалби

11.11.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-439M

3.8B

Предишно отваряне

30.95

Предишно затваряне

33.64

Настроения в новините

By Acuity

100%

0%

361 / 371 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

Zai Lab Ltd ADR Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

7.10.2025 г., 16:58 ч. UTC

Печалби

BMW Trims 2025 View, Citing Weaker Performance in China

7.10.2025 г., 23:43 ч. UTC

Пазарно говорене

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

7.10.2025 г., 23:36 ч. UTC

Пазарно говорене

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

7.10.2025 г., 23:19 ч. UTC

Пазарно говорене

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

7.10.2025 г., 22:50 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

7.10.2025 г., 22:50 ч. UTC

Пазарно говорене

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

7.10.2025 г., 22:40 ч. UTC

Пазарно говорене

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

7.10.2025 г., 21:56 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

7.10.2025 г., 21:56 ч. UTC

Пазарно говорене

Australia Shares Set to Start Day Roughly Flat -- Market Talk

7.10.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

7.10.2025 г., 20:44 ч. UTC

Горещи акции

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

7.10.2025 г., 19:42 ч. UTC

Пазарно говорене

Treasury Yields Fall as Data Blackout Continues -- Market Talk

7.10.2025 г., 19:23 ч. UTC

Придобивния, сливания и поглъщания

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

7.10.2025 г., 19:07 ч. UTC

Пазарно говорене

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

7.10.2025 г., 19:02 ч. UTC

Пазарно говорене

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

7.10.2025 г., 16:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

7.10.2025 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

7.10.2025 г., 16:20 ч. UTC

Пазарно говорене

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

7.10.2025 г., 16:15 ч. UTC

Пазарно говорене

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

7.10.2025 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

7.10.2025 г., 15:37 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

7.10.2025 г., 15:37 ч. UTC

Пазарно говорене

Markets for Canadian Aluminum Open Up Beyond U.S. -- Market Talk

7.10.2025 г., 15:33 ч. UTC

Пазарно говорене

Gold Rise Tied to Lower Confidence in Dollar Assets -- Market Talk

7.10.2025 г., 15:25 ч. UTC

Пазарно говорене

Canadian Mining Stocks Rally on U.S. Defense Dept. Deal -- Market Talk

7.10.2025 г., 15:15 ч. UTC

Пазарно говорене

Investors Look to Gold, Bitcoin as Traditional Correlations Break Down -- Market Talk

7.10.2025 г., 15:04 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

7.10.2025 г., 15:04 ч. UTC

Пазарно говорене

Canadian Aluminum Exports Squeezed by Tariffs -- Market Talk

7.10.2025 г., 14:56 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

7.10.2025 г., 14:56 ч. UTC

Пазарно говорене

U.S. Government Shutdown May Impact Release of Canadian Trade Data -- Market Talk

7.10.2025 г., 14:52 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Tesla, AMD, Ford, Dell, IBM, AppLovin, Trilogy Metals, Aehr, and More -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Zai Lab Ltd ADR Прогноза

Ценова цел

By TipRanks

59.84% нагоре

12-месечна прогноза

Среден 52.57 USD  59.84%

Висок 69 USD

Нисък 39 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за Zai Lab Ltd ADR през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

7 ratings

6

Купи

1

Задържане

0

Продай

Техническа оценка

By Trading Central

28.13 / 31.12Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Bearish Evidence

Дългосрочен план

Bullish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.
help-icon Live chat